Tag: IPO
-
Cancer Immunotherapy Biotech Issues $80M IPO
A biotechnology company designing immunotherapies for solid tumor cancers with a patient’s white blood cells is raising $80 million in its initial public offering or IPO.
-
Gut-Brain Meds Developer Going Public in Merger
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, in a deal expected to…
-
Digital Mental Therapy Company to Go Public in Merger
A creator of game therapies for cognitive impairments is becoming a publicly-traded company through a special purpose acquisition company or SPAC.
-
Synthetic Antibody Company Goes Public in $230M Merger
A developer of synthetic antibodies for inflammatory and skin disorders is becoming a public company through a special purpose acquisition-merger.
-
RNA Manufacturer Goes Public in $282M Merger
A company producing synthetic RNA for agricultural and biomedical applications is now a public company after a special-purpose acquisition.
-
Synthetic Bio Company Goes Public in $2.5B Merger
A company developing synthetic biology and engineering tools for biotechnology is becoming a public company through a special-purpose acquisition.
-
Biomanufacturing Materials Company Issues $500M IPO
Zymergen Inc., a developer of materials made with synthetic biology for industrial products is raising $500 million in its initial public stock offering.
-
Engineered Cell Therapy Company Issues $588M IPO
A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO.
-
2020 Venture Funds Mixed, Biotech Keeps Sizzling
Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020.
-
Covid-19 Antibody Developer Raises $483M in IPO
A biotechnology company developing therapeutic antibodies for Covid-19 infections is raising $483 million in its initial public offering of common stock.